Skip to main content
SpringerLink
Log in

LAG-3 in Cancer Immunotherapy

  • Chapter
  • First Online:
Cancer Immunology and Immunotherapy

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 344))

Abstract

LAG-3 (CD223) is a cell surface molecule expressed on activated T cells (Huard et al. Immunogenetics 39:213–217, 1994), NK cells (Triebel et al. J Exp Med 171:1393–1405, 1990), B cells (Kisielow et al. Eur J Immunol 35:2081–2088, 2005), and plasmacytoid dendritic cells (Workman et al. J Immunol 182:1885–1891, 2009) that plays an important but incompletely understood role in the function of these lymphocyte subsets. In addition, the interaction between LAG-3 and its major ligand, Class II MHC, is thought to play a role in modulating dendritic cell function (Andreae et al. J Immunol 168:3874–3880, 2002). Recent preclinical studies have documented a role for LAG-3 in CD8 T cell exhaustion (Blackburn et al. Nat Immunol 10:29–37, 2009), and blockade of the LAG-3/Class II interaction using a LAG-3 Ig fusion protein is being evaluated in a number of clinical trials in cancer patients. In this review, we will first discuss the basic structural and functional biology of LAG-3, followed by a review of preclinical and clinical data pertinent to a role for LAG-3 in cancer immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Andreae S, Piras F et al (2002) Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223). J Immunol 168:3874–3880

    PubMed  CAS  Google Scholar 

  • Angevin E, Kremer F et al (1997) Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity. Int J Cancer 72:431–440

    Article  PubMed  CAS  Google Scholar 

  • Annunziato F, Manetti R et al (1996) Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production. FASEB J 10:769–776

    PubMed  CAS  Google Scholar 

  • Annunziato F, Manetti R et al (1997) Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells. Eur J Immunol 27:2239–2244

    Article  PubMed  CAS  Google Scholar 

  • Baixeras E, Huard B et al (1992) Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med 176:327–337

    Article  PubMed  CAS  Google Scholar 

  • Blackburn SD, Shin H et al (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10:29–37

    Article  PubMed  CAS  Google Scholar 

  • Brignone C, Grygar C et al (2007a) IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study. Vaccine 25:4641–4650

    Article  PubMed  CAS  Google Scholar 

  • Brignone C, Grygar C et al (2007b) IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines 5:5

    Article  PubMed  Google Scholar 

  • Brignone C, Escudier B et al (2009) A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 15:6225–6231

    Article  PubMed  CAS  Google Scholar 

  • Brignone C, Gutierrez M et al (2010) First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 8:71

    Article  PubMed  Google Scholar 

  • Camisaschi C, Casati C et al (2010) LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 184:6545–6551

    Article  PubMed  CAS  Google Scholar 

  • Cappello P, Triebel F et al (2003) LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice, 1. Cancer Res 63:2518–2525

    PubMed  CAS  Google Scholar 

  • Demeure CE, Wolfers J et al (2001) T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts 1. Eur J Cancer 37:1709–1718

    Article  PubMed  CAS  Google Scholar 

  • Dijkstra JM, Somamoto T et al (2006) Identification and characterization of a second CD4-like gene in teleost fish. Mol Immunol 43:410–419

    Article  PubMed  CAS  Google Scholar 

  • El MS, Triebel F (2000) A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J Immunol 164:5583–5589

    Google Scholar 

  • Fleury S, Lamarre D et al (1991) Mutational analysis of the interaction between CD4 and class II MHC: class II antigens contact CD4 on a surface opposite the gp120-binding site. Cell 66:1037–1049

    Article  PubMed  CAS  Google Scholar 

  • Gandhi MK, Lambley E et al (2006) Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 108:2280–2289

    Article  PubMed  CAS  Google Scholar 

  • Grosso JF, Kelleher CC et al (2007) LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 117:3383–3392

    Article  PubMed  CAS  Google Scholar 

  • Grosso JF, Goldberg MV et al (2009) Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 182:6659–6669

    Article  PubMed  CAS  Google Scholar 

  • Hannier S, Triebel F (1999) The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes. Int Immunol 11:1745–1752

    Article  PubMed  CAS  Google Scholar 

  • Huang CT, Workman CJ et al (2004) Role of LAG-3 in regulatory T cells. Immunity 21:503–513

    Article  PubMed  CAS  Google Scholar 

  • Huard B, Gaulard P et al (1994) Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics 39:213–217

    Article  PubMed  CAS  Google Scholar 

  • Huard B, Prigent P et al (1995) CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol 25:2718–2721

    Article  PubMed  CAS  Google Scholar 

  • Huard B, Mastrangeli R et al (1997) Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci USA 94:5744–5749

    Article  PubMed  CAS  Google Scholar 

  • Huard B, Tournier M et al (1998) LAG-3 does not define a specific mode of natural killing in human. Immunol Lett 61:109–112

    Article  PubMed  CAS  Google Scholar 

  • Joosten SA, van Meijgaarden KE et al (2007) Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci USA 104:8029–8034

    Article  PubMed  CAS  Google Scholar 

  • Kapp JA, Bucy RP (2008) CD8+ suppressor T cells resurrected. Hum Immunol 69:715–720

    Article  PubMed  CAS  Google Scholar 

  • Kisielow M, Kisielow J et al (2005) Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells 2. Eur J Immunol 35:2081–2088

    Article  PubMed  CAS  Google Scholar 

  • Li N, Wang Y et al (2007) Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J 26:494–504

    Article  PubMed  CAS  Google Scholar 

  • Liang B, Workman C et al (2008) Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 180:5916–5926

    PubMed  CAS  Google Scholar 

  • Macon-Lemaitre L, Triebel F (2005) The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 115:170–178

    Article  PubMed  CAS  Google Scholar 

  • Matsuzaki J, Gnjatic S et al (2010) Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA 107:7875–7880

    Article  PubMed  CAS  Google Scholar 

  • Miyazaki T, Dierich A et al (1996) LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice. Int Immunol 8:725–729

    Article  PubMed  CAS  Google Scholar 

  • Moebius U, Pallai P et al (1993) Delineation of an extended surface contact area on human CD4 involved in class II major histocompatibility complex binding. Proc Natl Acad Sci USA 90:8259–8263

    Article  PubMed  CAS  Google Scholar 

  • Peggs KS, Quezada SA et al (2009) Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206:1717–1725

    Article  PubMed  CAS  Google Scholar 

  • Prigent P, El MS et al (1999) Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses. Eur J Immunol 29:3867–3876

    Article  PubMed  CAS  Google Scholar 

  • Rogala B, Gluck J et al (2002) Do the molecules CD26 and lymphocytes activation gene-3 differentiate between type 1 and 2 T cell response? J Investig Allergol Clin Immunol 12:198–203

    PubMed  CAS  Google Scholar 

  • Subramanyam M, Wands G et al (1998) Soluble human lymphocyte activation gene-3 modulates allospecific T cell responses. Int Immunol 10:679–689

    Article  PubMed  CAS  Google Scholar 

  • Triebel F, Jitsukawa S et al (1990) LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 171:1393–1405

    Article  PubMed  CAS  Google Scholar 

  • Triebel F, Hacene K et al (2006) A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett 235:147–153

    Article  PubMed  CAS  Google Scholar 

  • Woo SR, Li N et al (2010) Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4. Eur J Immunol 40:1768–1777

    Article  PubMed  CAS  Google Scholar 

  • Workman CJ, Vignali DA (2003) The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells, 1. Eur J Immunol 33:970–979

    Article  PubMed  CAS  Google Scholar 

  • Workman CJ, Dugger KJ et al (2002) Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3, 2. J Immunol 169:5392–5395

    PubMed  CAS  Google Scholar 

  • Workman CJ, Cauley LS et al (2004) Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol 172:5450–5455

    PubMed  CAS  Google Scholar 

  • Workman CJ, Wang Y et al (2009) LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol 182:1885–1891

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins Kimmel Cancer Center, 1650 Orleans Street – CRB 423, Baltimore, MD, 21231, USA

    Monica V. Goldberg & Charles G. Drake

Authors
  1. Monica V. Goldberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles G. Drake
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles G. Drake .

Editor information

Editors and Affiliations

  1. , Medical Oncology/Hematologic Neoplasial, Dana-Farber Cancer Institute, Binney Street 44, Boston, 02115, Massachusetts, USA

    Glenn Dranoff

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Goldberg, M.V., Drake, C.G. (2010). LAG-3 in Cancer Immunotherapy. In: Dranoff, G. (eds) Cancer Immunology and Immunotherapy. Current Topics in Microbiology and Immunology, vol 344. Springer, Berlin, Heidelberg. https://doi.org/10.1007/82_2010_114

Download citation

Publish with us

Policies and ethics

Search

Navigation